Teva Pharmaceutical Industries (TEVA) Return on Sales (2016 - 2025)
Historic Return on Sales for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 0.15%.
- Teva Pharmaceutical Industries' Return on Sales rose 2100.0% to 0.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.09%, marking a year-over-year increase of 1600.0%. This contributed to the annual value of 0.08% for FY2025, which is 2000.0% up from last year.
- Latest data reveals that Teva Pharmaceutical Industries reported Return on Sales of 0.15% as of Q4 2025, which was up 2100.0% from 0.1% recorded in Q3 2025.
- Teva Pharmaceutical Industries' 5-year Return on Sales high stood at 0.15% for Q4 2025, and its period low was 0.4% during Q4 2023.
- Over the past 5 years, Teva Pharmaceutical Industries' median Return on Sales value was 0.01% (recorded in 2021), while the average stood at 0.05%.
- In the last 5 years, Teva Pharmaceutical Industries' Return on Sales skyrocketed by 12000bps in 2021 and then plummeted by -3100bps in 2022.
- Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Return on Sales stood at 0.04% in 2021, then plummeted by -833bps to 0.34% in 2022, then dropped by -17bps to 0.4% in 2023, then soared by 84bps to 0.07% in 2024, then soared by 325bps to 0.15% in 2025.
- Its Return on Sales stands at 0.15% for Q4 2025, versus 0.1% for Q3 2025 and 0.07% for Q2 2025.